An adjunctive antidepressant nutraceutical combination in treating major depression: study protocol, and clinical considerations

Sarris, Jerome, Stough, Con, Bousman, Chad, Murphy, Jenifer, Savage, Karen, Smith, Deidre J., Menon, Ranjit, Chamoli, Suneel, Oliver, Georgina, Berk, Michael, Byrne, Gerard J., Ng, Chee and Mischoulon, David (2015) An adjunctive antidepressant nutraceutical combination in treating major depression: study protocol, and clinical considerations. Advances in Integrative Medicine, 2 1: 49-55. doi:10.1016/j.aimed.2015.02.001


Author Sarris, Jerome
Stough, Con
Bousman, Chad
Murphy, Jenifer
Savage, Karen
Smith, Deidre J.
Menon, Ranjit
Chamoli, Suneel
Oliver, Georgina
Berk, Michael
Byrne, Gerard J.
Ng, Chee
Mischoulon, David
Title An adjunctive antidepressant nutraceutical combination in treating major depression: study protocol, and clinical considerations
Journal name Advances in Integrative Medicine   Check publisher's open access policy
ISSN 2212-9588
2212-9596
Publication date 2015-04
Sub-type Article (original research)
DOI 10.1016/j.aimed.2015.02.001
Open Access Status Not Open Access
Volume 2
Issue 1
Start page 49
End page 55
Total pages 7
Place of publication Amsterdam, Netherlands
Publisher Elsevier
Collection year 2016
Language eng
Abstract Current treatment for major depressive disorder (MDD), a prevalent and disabling mental illness, is inadequate, with two-thirds of people treated with first-line antidepressants not achieving remission. MDD is for many a chronic condition, often requiring multiple treatment attempts, thus development of additional interventions is urgently required. An emerging approach to improve non-response to antidepressants is the use of adjunctive nutraceuticals. The pathophysiology of MDD is considered to involve a range of abnormalities (monoamine impairment, neuro-endocrinological changes, reduced brain-derived neurotrophic factor, and cytokine alterations). By targeting an array of these key neurobiological pathways via specific nutraceuticals (S-adenosyl methionine; [SAMe], 5-HTP [active tryptophan], folinic acid [active folic acid], omega-3 fatty acids, and zinc), there is the potential to provide a more comprehensive therapeutic biological approach to treat depression. We are currently conducting a National Health and Medical Research Council funded study in Australia (APP1048222). The clinical trial is phase II/III, multi-site, 3-arm, 8-week, randomised, double-blind, placebo-controlled study using SAMe + folinic acid versus a combination nutraceutical (SAMe, 5-HTP, folinic acid, omega-3, and zinc) or matching placebo in 300 currently depressed participants with diagnosed MDD who are non-responsive to current antidepressants (ANZCTR, protocol number: 12613001300763). The results may provide evidence for a novel adjunctive neurobiological approach for treating depression.
Keyword Antidepressant
Depression
Nutraceutical
Nutrient
Omega-3
Protocol
RCT
S-Adenosyl methionine
SAMe
Q-Index Code C1
Q-Index Status Confirmed Code
Institutional Status UQ

Document type: Journal Article
Sub-type: Article (original research)
Collections: Official 2016 Collection
School of Medicine Publications
 
Versions
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 1 times in Thomson Reuters Web of Science Article | Citations
Scopus Citation Count Cited 0 times in Scopus Article
Google Scholar Search Google Scholar
Created: Tue, 26 May 2015, 02:25:17 EST by System User on behalf of Scholarly Communication and Digitisation Service